장시간 작용형 주사 치료제 시장 : 기술별, 기간별, 적응증별, 투여 경로별, 최종사용자별 - 시장 규모, 업계 동향, 기회 분석 및 예측(2026-2035년)

The global long-acting injectable therapeutics market is experiencing strong revenue growth, reflecting increasing demand for treatment options that can provide sustained drug delivery over extended periods. The market is estimated to be valued at approximately USD 14 billion in 2025, indicating the growing commercial importance of long-acting formulations across a range of therapeutic applications.

The market is projected to expand substantially over the coming decade, reaching an estimated value of USD 45 billion by 2035. Between 2026 and 2035, the market is projected to grow at a compound annual growth rate (CAGR) of 12.4%. This represents a significant increase in market size and highlights the expanding role of long-acting injectable technologies in pharmaceutical treatment.

Noteworthy Market Developments

The competitive landscape of the long-acting injectable therapeutics market includes several pharmaceutical companies with established portfolios spanning psychiatry, infectious diseases, addiction treatment, oncology, cardiovascular care, and other therapeutic areas. Among the prominent participants are Johnson & Johnson, GSK through ViiV Healthcare, Otsuka Pharmaceutical, Alkermes, and Novartis.

These companies illustrate the breadth of competition within the long-acting injectable therapeutics market. Their portfolios cover different therapeutic areas and employ different approaches to sustained drug delivery, including depot antipsychotics, long-acting antiretroviral injections, extended-release formulations for substance-use disorders, and subcutaneous therapies designed for infrequent administration. Continued development of longer dosing intervals, alternative injection routes, specialized formulations, and patient-oriented delivery systems is likely to remain an important component of competition as pharmaceutical companies seek to expand the clinical applications and commercial reach of long-acting therapeutics.

Core Growth Drivers

The growing demand for long-acting injectable therapies is strongly associated with the need to address medication fatigue and challenges with treatment adherence, particularly among patients managing chronic and lifelong conditions. Conventional oral therapies often require patients to follow a daily medication schedule over extended periods, sometimes involving multiple medicines and multiple doses each day. Over time, this continuous requirement can become burdensome and may contribute to missed, delayed, or inconsistent doses. Long-acting injectable formulations provide an alternative approach by extending the interval between administrations and reducing the frequency with which patients need to actively remember and take medication.

Emerging Opportunity Trends

The shift from intramuscular (IM) to subcutaneous (SC) delivery is emerging as an important opportunity for growth in the long-acting injectable therapeutics market. While intramuscular administration has traditionally been widely used for depot and sustained-release formulations, pharmaceutical development is increasingly exploring subcutaneous delivery systems that can provide prolonged drug release while potentially offering a more convenient administration experience. This transition is being supported by advances in formulation technologies, drug-delivery devices, and sustained-release mechanisms that enable therapeutic agents to be delivered effectively through the subcutaneous tissue.

Barriers to Optimization

High manufacturing complexity and elevated production costs may act as significant restraints on the growth of the long-acting injectable therapeutics market. Unlike conventional oral formulations, long-acting injectable products often require sophisticated drug-delivery technologies, specialized manufacturing processes, and stringent quality-control procedures. The development and production of depot formulations, microspheres, suspensions, and other sustained-release systems can involve multiple processing stages, making manufacturing more technically demanding and resource-intensive.

Detailed Market Segmentation

By duration, the weekly-to-monthly sub-segment accounted for the largest share of the market in 2025, supported by the growing adoption of long-acting therapies designed to maintain therapeutic drug exposure over extended intervals. Formulations administered on a weekly or monthly basis provide an intermediate balance between treatment frequency and sustained drug delivery. Compared with therapies requiring daily administration, these regimens can reduce the number of dosing occasions while still allowing healthcare professionals to monitor treatment progress at regular intervals.

By indication, psychiatry, particularly the treatment of schizophrenia and bipolar disorder, accounted for the largest share of the market in 2025. The strong position of this segment is closely associated with the importance of maintaining consistent treatment over prolonged periods in patients with chronic psychiatric conditions. Long-term pharmacological management is often an important component of preventing symptom recurrence and supporting disease stability. Consequently, therapeutic approaches that can provide sustained drug exposure and reduce interruptions in treatment have attracted significant attention within the psychiatric care landscape.

By route of administration, intramuscular administration emerged as the dominant route in the long-acting injectable therapeutics market during 2025. Its widespread adoption can be attributed to its suitability for delivering formulations designed to release active pharmaceutical ingredients gradually over an extended period. Intramuscular injections allow long-acting formulations to be deposited directly into muscle tissue, where the medication can form a depot and subsequently be released into systemic circulation in a controlled manner. This characteristic makes the route particularly appropriate for depot suspensions, polymer-based microspheres, and other formulations intended to provide prolonged therapeutic effects.

By end user, hospitals are expected to account for the largest share of the market in 2025, reflecting their central role in the administration and clinical management of depot injections. Hospitals serve as the primary point of care for patients receiving these treatments, particularly during the initial stages of therapy when close medical supervision is often required. The controlled environment of hospital settings allows healthcare professionals to assess patients before administration, ensure appropriate dosing, observe treatment responses, and address any immediate complications or adverse reactions that may occur following the injection.

Segment Breakdown

By Technology

• Polymeric Microspheres
• In-Situ Forming Gels/Depots
• Crystalline Suspensions
• Implants
• Lipid-Based Depots

By Duration

• Weekly-Monthly
• Quarterly
• Six-Month and Longer

By Indication

• Psychiatry (Schizophrenia, Bipolar)
• HIV Treatment & Prevention
• Oncology & Hormonal
• Substance Use Disorder
• Metabolic/Obesity
• Ophthalmology

By Route

• Intramuscular
• Subcutaneous
• Intraocular/Local

By End User

• Hospitals
• Specialty Clinics
• Homecare & Community Health

By Region

• North America
• The U.S.
• Canada
• Mexico
• Europe
• Western Europe
• The UK
• Germany
• France
• Italy
• Spain
• Rest of Western Europe
• Eastern Europe
• Poland
• Russia
• Rest of Eastern Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East & Africa (MEA)
• Saudi Arabia
• South Africa
• UAE
• Rest of MEA
• South America
• Argentina
• Brazil
• Rest of South America
• Geography Analysis
• North America commands the apex position as the dominant region in the long-acting injectable therapeutics market, capturing over 45% of global revenue. This undeniable stronghold is propelled by the early commercialization of advanced depot formulations and highly structured reimbursement frameworks under major public healthcare initiatives like Medicare and Medicaid, which facilitate steady clinical adoption and market penetration.
• The United States unequivocally anchors this regional dominance, contributing an estimated 85% of total sales through its advanced healthcare infrastructure and high patient demand for optimized chronic care management. Within this ecosystem, US-based pharmaceutical giants continuously channel heavy investments exceeding USD 2 billion into next-generation polymer matrices and microsphere technologies, specifically targeting enhanced delivery mechanisms for psychiatric and endocrine applications.
• Meanwhile, Canada further bolsters regional growth by systematically integrating these sustained-release therapies into provincial mental health programs. By streamlining access to extended-release medications, the Canadian healthcare system effectively mitigates high hospital readmission rates, ensuring long-term therapeutic compliance and optimizing outpatient care outcomes across provinces.

Table of Content

Chapter 1. Executive Summary

• 1.1. Global Long-Acting Injectable Therapeutics Market

Chapter 2. Research Methodology & Research Framework

• 2.1. Research Objective
• 2.2. Product Overview
• 2.3. Market Segmentation
• 2.4. Qualitative Research
  • 2.4.1. Primary Sources
  • 2.4.2. Secondary Sources
• 2.5. Quantitative Research
  • 2.5.1. Primary Sources
  • 2.5.2. Secondary Sources
• 2.6. Breakdown of Primary Research Respondents, By Region
• 2.7. Assumption for Study
• 2.8. Market Size Estimation
• 2.9. Data Triangulation

Chapter 3. Global Long-Acting Injectable Therapeutics Market Overview

• 3.1. Industry Value Chain Analysis
  • 3.1.1. PLGA Polymer/Biomaterial & API Suppliers
  • 3.1.2. LAI Formulation (Microsphere, In-Situ Gel, Crystalline Suspension, Implant) Developers
  • 3.1.3. Sterile Fill-Finish, Device (Prefilled Syringe/Autoinjector) & Cold-Chain Manufacturing
  • 3.1.4. Clinical Development, Regulatory (Q3 Bioequivalence) & Payer Partners
  • 3.1.5. End Users (Hospitals, Specialty Clinics, Homecare & Community Health)
• 3.2. Industry Outlook
  • 3.2.1. Overview of the Global Long-Acting Injectable (LAI) Therapeutics Industry
  • 3.2.2. Adherence / "Pill Fatigue" Solution Driving LAI Adoption in Psychiatry, HIV PrEP/ART & Metabolic Disease
  • 3.2.3. Ultra-Long-Acting (Biannual Lenacapavir), IM-to-Subcutaneous Self-Administration Shift, PLGA/AI-QbD Polymer Engineering, Q3-Bioequivalence Generic Barrier & GLP-1 Monthly LAI Pipeline
• 3.3. PESTLE Analysis
• 3.4. Porter's Five Forces Analysis
  • 3.4.1. Bargaining Power of Suppliers
  • 3.4.2. Bargaining Power of Buyers
  • 3.4.3. Threat of New Entrants
  • 3.4.4. Threat of Substitutes
  • 3.4.5. Intensity of Rivalry
• 3.5. Market Growth and Outlook
  • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
  • 3.5.2. Price Trend Analysis, By Technology

Chapter 4. Global Long-Acting Injectable Therapeutics Market Analysis

• 4.1. Competition Dashboard
  • 4.1.1. Market Concentration Rate
  • 4.1.2. Company Market Share Analysis (Value %), 2025
  • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Long-Acting Injectable Therapeutics Market Analysis

• 5.1. Market Dynamics and Trends
  • 5.1.1. Growth Drivers
  • 5.1.2. Restraints
  • 5.1.3. Opportunity
  • 5.1.4. Key Trends
• 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 5.2.1. By Technology
    • 5.2.1.1. Key Insights
      • 5.2.1.1.1. Polymeric Microspheres
      • 5.2.1.1.2. In-Situ Forming Gels/Depots
      • 5.2.1.1.3. Crystalline Suspensions
      • 5.2.1.1.4. Implants
      • 5.2.1.1.5. Lipid-Based Depots
  • 5.2.2. By Duration
    • 5.2.2.1. Key Insights
      • 5.2.2.1.1. Weekly-Monthly
      • 5.2.2.1.2. Quarterly
      • 5.2.2.1.3. Six-Month and Longer
  • 5.2.3. By Indication
    • 5.2.3.1. Key Insights
      • 5.2.3.1.1. Psychiatry (Schizophrenia, Bipolar)
      • 5.2.3.1.2. HIV Treatment & Prevention
      • 5.2.3.1.3. Oncology & Hormonal
      • 5.2.3.1.4. Substance Use Disorder
      • 5.2.3.1.5. Metabolic/Obesity
      • 5.2.3.1.6. Ophthalmology
  • 5.2.4. By Route
    • 5.2.4.1. Key Insights
      • 5.2.4.1.1. Intramuscular
      • 5.2.4.1.2. Subcutaneous
      • 5.2.4.1.3. Intraocular/Local
  • 5.2.5. By End User
    • 5.2.5.1. Key Insights
      • 5.2.5.1.1. Hospitals
      • 5.2.5.1.2. Specialty Clinics
      • 5.2.5.1.3. Homecare & Community Health
  • 5.2.6. By Region
    • 5.2.6.1. Key Insights
      • 5.2.6.1.1. North America
        • 5.2.6.1.1.1. The U.S.
        • 5.2.6.1.1.2. Canada
        • 5.2.6.1.1.3. Mexico
      • 5.2.6.1.2. Europe
        • 5.2.6.1.2.1. Western Europe
          • 5.2.6.1.2.1.1. The UK
          • 5.2.6.1.2.1.2. Germany
          • 5.2.6.1.2.1.3. France
          • 5.2.6.1.2.1.4. Italy
          • 5.2.6.1.2.1.5. Spain
          • 5.2.6.1.2.1.6. Rest of Western Europe
        • 5.2.6.1.2.2. Eastern Europe
          • 5.2.6.1.2.2.1. Poland
          • 5.2.6.1.2.2.2. Russia
          • 5.2.6.1.2.2.3. Rest of Eastern Europe
      • 5.2.6.1.3. Asia Pacific
        • 5.2.6.1.3.1. China
        • 5.2.6.1.3.2. India
        • 5.2.6.1.3.3. Japan
        • 5.2.6.1.3.4. Australia & New Zealand
        • 5.2.6.1.3.5. South Korea
        • 5.2.6.1.3.6. ASEAN
        • 5.2.6.1.3.7. Rest of Asia Pacific
      • 5.2.6.1.4. Middle East & Africa (MEA)
        • 5.2.6.1.4.1. Saudi Arabia
        • 5.2.6.1.4.2. South Africa
        • 5.2.6.1.4.3. UAE
        • 5.2.6.1.4.4. Rest of MEA
      • 5.2.6.1.5. South America
        • 5.2.6.1.5.1. Argentina
        • 5.2.6.1.5.2. Brazil
        • 5.2.6.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

• 6.1. Market Dynamics and Trends
  • 6.1.1. Growth Drivers
  • 6.1.2. Restraints
  • 6.1.3. Opportunity
  • 6.1.4. Key Trends
• 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 6.2.1. Key Insights
    • 6.2.1.1. By Technology
    • 6.2.1.2. By Duration
    • 6.2.1.3. By Indication
    • 6.2.1.4. By Route
    • 6.2.1.5. By End User
    • 6.2.1.6. By Country

Chapter 7. Europe Market Analysis

• 7.1. Market Dynamics and Trends
  • 7.1.1. Growth Drivers
  • 7.1.2. Restraints
  • 7.1.3. Opportunity
  • 7.1.4. Key Trends
• 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 7.2.1. Key Insights
    • 7.2.1.1. By Technology
    • 7.2.1.2. By Duration
    • 7.2.1.3. By Indication
    • 7.2.1.4. By Route
    • 7.2.1.5. By End User
    • 7.2.1.6. By Country

Chapter 8. Asia Pacific Market Analysis

• 8.1. Market Dynamics and Trends
  • 8.1.1. Growth Drivers
  • 8.1.2. Restraints
  • 8.1.3. Opportunity
  • 8.1.4. Key Trends
• 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 8.2.1. Key Insights
    • 8.2.1.1. By Technology
    • 8.2.1.2. By Duration
    • 8.2.1.3. By Indication
    • 8.2.1.4. By Route
    • 8.2.1.5. By End User
    • 8.2.1.6. By Country

Chapter 9. Middle East & Africa (MEA) Market Analysis

• 9.1. Market Dynamics and Trends
  • 9.1.1. Growth Drivers
  • 9.1.2. Restraints
  • 9.1.3. Opportunity
  • 9.1.4. Key Trends
• 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 9.2.1. Key Insights
    • 9.2.1.1. By Technology
    • 9.2.1.2. By Duration
    • 9.2.1.3. By Indication
    • 9.2.1.4. By Route
    • 9.2.1.5. By End User
    • 9.2.1.6. By Country

Chapter 10. South America Market Analysis

• 10.1. Market Dynamics and Trends
  • 10.1.1. Growth Drivers
  • 10.1.2. Restraints
  • 10.1.3. Opportunity
  • 10.1.4. Key Trends
• 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
  • 10.2.1. Key Insights
    • 10.2.1.1. By Technology
    • 10.2.1.2. By Duration
    • 10.2.1.3. By Indication
    • 10.2.1.4. By Route
    • 10.2.1.5. By End User
    • 10.2.1.6. By Country

Chapter 11. Company Profile

Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 11.1. Johnson & Johnson
• 11.2. GSK (ViiV Healthcare)
• 11.3. Otsuka Pharmaceutical
• 11.4. Alkermes
• 11.5. Novartis
• 11.6. Gilead Sciences
• 11.7. Teva Pharmaceuticals
• 11.8. Medincell
• 11.9. Lupin
• 11.10. Amneal Pharmaceuticals
• 11.11. Daewoong Pharmaceutical
• 11.12. Lundbeck
• 11.13. Other Prominent Players

Chapter 12. Annexure

• 12.1. List of Secondary Sources
• 12.2. Key Country Markets- Macro Economic Outlook/Indicators